Directorio

If you choose to join our registry, you will read and sign a consent form and then complete a brief survey about your health history.

Our Duke Health and Exercise Research Trials Registry is a way for people to let our team know that they are interested in learning more about any of our studies for which they may qualify. Our studies include both healthy people and those who may have certain medical conditions.

We created the Duke Clinical Research Volunteer Registry for people who would like to join clinical research studies. We will use this registry to contact you about available studies. For more information or to sign up, visit us at: https://redcap.duke.edu/redcap/surveys/?s=X4T7JKHPX4

A registry is a database of information (data) about patients living with a specific condition. Scientists study the information in the registry to increase what we know about the condition so we can develop better treatments in the future. This registry will help us better understand lupus and how it is managed, including how different treatments work and their long-term safety.

You will review a consent form and share some basic information about your health and what kinds of research interest you. Later, you may be asked to join a brain health study. Being in ADD ME does not mean you have to join any study.

We are doing this study to look at components of the blood to see if there are features that distinguish people with dystonia from people without dystonia. Identifying "biomarkers" in the blood that are associated with dystonia is greatly needed to help more accurately diagnosis dystonia and to identify subsets of dystonias that may have shared mechanisms. Being able to group individuals by underlying mechanisms can guide people with dystonia to the most appropriate future treatments that act specifically to correct one cause or another.

We are doing this study to find out if infusing chemotherapy drugs directly into the hepatic artery (the blood vessel that supplies blood to the liver) is a better treatment option than standard chemotherapy for people who have colorectal cancer that has spread to the liver.

We are doing this study to compare the results of typical chemotherapy on its own to high dose chemotherapy followed by stem cell infusion after completing the usual chemotherapy. We want to know which option has the best outcomes for people with periperhal T-cell lymphoma.